These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 35097007)

  • 21. Influence of SGLT2i and RAASi and Their Combination on Risk of Hyperkalemia in DKD: A Network Meta-Analysis.
    Luo X; Xu J; Zhou S; Xue C; Chen Z; Mao Z
    Clin J Am Soc Nephrol; 2023 Aug; 18(8):1019-1030. PubMed ID: 37256921
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Heart Failure Therapies following Acute Coronary Syndromes with Reduced Ejection Fraction: Data from the ACSIS Survey.
    Zafrir B; Ovdat T; Abu Akel M; Bahouth F; Orvin K; Beigel R; Amir O; Elbaz-Greener G
    J Pers Med; 2023 Jun; 13(6):. PubMed ID: 37374004
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Optimization of Guideline-Directed Medical Therapy during Hospitalization among Patients with Heart Failure with Reduced Ejection Fraction in Daily Clinical Practice.
    Bánfi-Bacsárdi F; Muk B; Pilecky D; Duray GZ; Kiss RG; Nyolczas N
    Cardiology; 2023; 148(1):27-37. PubMed ID: 36470212
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Variation in use and dosing escalation of renin angiotensin system, mineralocorticoid receptor antagonist, angiotensin receptor neprilysin inhibitor and beta-blocker therapies in heart failure and reduced ejection fraction: Association of comorbidities.
    Albert NM; Tyson RJ; Hill CL; DeVore AD; Spertus JA; Duffy C; Butler J; Patterson JH; Hernandez AF; Williams FB; Thomas L; Fonarow GC
    Am Heart J; 2021 May; 235():82-96. PubMed ID: 33497697
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Angiotensin Receptor-Neprilysin Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction and Advanced Chronic Kidney Disease: A Retrospective Multi-Institutional Study.
    Hsiao FC; Lin CP; Yu CC; Tung YC; Chu PH
    Front Cardiovasc Med; 2022; 9():794707. PubMed ID: 35360037
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of Digoxin Use on Guideline-Directed Medical Therapy in Patients With Heart Failure With Reduced Ejection Fraction.
    Jabri A; Alhuneafat L; Shahrori Z; Hamade H; Nasser F; Rayyan A; Mhanna M; Al Abdouh A; Haddadin F; Balakumaran K
    J Clin Med Res; 2022 Aug; 14(8):315-320. PubMed ID: 36128010
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Higher versus lower doses of ACE inhibitors, angiotensin-2 receptor blockers and beta-blockers in heart failure with reduced ejection fraction: Systematic review and meta-analysis.
    Turgeon RD; Kolber MR; Loewen P; Ellis U; McCormack JP
    PLoS One; 2019; 14(2):e0212907. PubMed ID: 30817783
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Renin-angiotensin-aldosterone system blockers for heart failure with reduced ejection fraction or left ventricular dysfunction: Network meta-analysis.
    Xie W; Zheng F; Song X; Zhong B; Yan L
    Int J Cardiol; 2016 Feb; 205():65-71. PubMed ID: 26720043
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Target Doses of Heart Failure Medical Therapy and Blood Pressure: Insights From the CHAMP-HF Registry.
    Peri-Okonny PA; Mi X; Khariton Y; Patel KK; Thomas L; Fonarow GC; Sharma PP; Duffy CI; Albert NM; Butler J; Hernandez AF; McCague K; Williams FB; DeVore AD; Patterson JH; Spertus JA
    JACC Heart Fail; 2019 Apr; 7(4):350-358. PubMed ID: 30738978
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cardiovascular and Renal Outcomes of Mineralocorticoid Receptor Antagonist Use in PARAGON-HF.
    Jering KS; Zannad F; Claggett B; Mc Causland FR; Ferreira JP; Desai A; Barkoudah E; McMurray JJV; Pfeffer MA; Solomon SD
    JACC Heart Fail; 2021 Jan; 9(1):13-24. PubMed ID: 33189633
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Heart failure drug titration, discontinuation, mortality and heart failure hospitalization risk: a multinational observational study (US, UK and Sweden).
    Savarese G; Bodegard J; Norhammar A; Sartipy P; Thuresson M; Cowie MR; Fonarow GC; Vaduganathan M; Coats AJS
    Eur J Heart Fail; 2021 Sep; 23(9):1499-1511. PubMed ID: 34132001
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Modern History RAAS Inhibition and Beta Blockade for Heart Failure to Underscore the Non-equivalency of ACEIs and ARBs.
    Hyman DA; Siebert VR; Birnbaum GD; Alam M; Birnbaum Y
    Cardiovasc Drugs Ther; 2020 Apr; 34(2):215-221. PubMed ID: 32219664
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of Efficacy and Safety of Angiotensin Receptor-Neprilysin Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction: A Meta-Analysis.
    Haseeb MT; Nouman Aslam M; Avanteeka F; Khalid UAR; Zubaer Ahmad D; Senaratne M; Almaalouli B; Hirani S
    Cureus; 2023 Mar; 15(3):e36392. PubMed ID: 37090394
    [TBL] [Abstract][Full Text] [Related]  

  • 34. SGLT2i versus ARNI in heart failure with reduced ejection fraction: a systematic review and meta-analysis.
    Yan Y; Liu B; Du J; Wang J; Jing X; Liu Y; Deng S; Du J; She Q
    ESC Heart Fail; 2021 Jun; 8(3):2210-2219. PubMed ID: 33749159
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of Prescribing Patterns of Renin-Angiotensin System Blockers and Beta-Blockers on Prognosis of Heart Failure.
    Kim HJ; Jo SH; Lee MH; Seo WW; Choi JO; Ryu KH
    Adv Ther; 2020 Sep; 37(9):3839-3849. PubMed ID: 32676928
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Translating the 2021 ESC heart failure guideline recommendations in daily practice: Results from a heart failure survey. A scientific statement of the ESC Council for Cardiology Practice and the Heart Failure Association of the ESC.
    Christodorescu R; Geavlete O; Ferrini M; Kümler T; Toutoutzas K; Bayes-Genis A; Seferovic P; Metra M; Chioncel O; Rosano GMC; Savarese G
    Eur J Heart Fail; 2024 Sep; ():. PubMed ID: 39318024
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Emerging concepts in heart failure management and treatment: focus on current guideline-directed medical therapy for heart failure with reduced ejection fraction.
    Ospina González OE; Llanos Mejía DC; Kaplinsky E; Barbagelata A; Perrone S
    Drugs Context; 2023; 12():. PubMed ID: 36660017
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Implementation of Guideline-Recommended Therapies for Patients With Heart Failure and Reduced Ejection Fraction: A Regional Arab Middle East Experience.
    Zubaid M; Rashed W; Ridha M; Bazargani N; Hamad A; Banna RA; Asaad N; Sulaiman K; Al-Jarallah M; Mulla AA; Baslaib F; AlMahmeed W
    Angiology; 2020 May; 71(5):431-437. PubMed ID: 32066246
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.
    Solomon SD; Claggett B; Desai AS; Packer M; Zile M; Swedberg K; Rouleau JL; Shi VC; Starling RC; Kozan Ö; Dukat A; Lefkowitz MP; McMurray JJ
    Circ Heart Fail; 2016 Mar; 9(3):e002744. PubMed ID: 26915374
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.